Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
HilleVax, Inc. HLVX
$14.10
+$0.03 (0.21%)
На 18:05, 12 мая 2023
+112.77%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
555024694.00000000
-
week52high
24.42
-
week52low
7.90
-
Revenue
0
-
P/E TTM
-2
-
Beta
0.00000000
-
EPS
-5.85000000
-
Last Dividend
0.00000000
-
Next Earnings Date
14 июн 2023 г. в 04:00
Описание компании
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | 24 мая 2022 г. | |
| Stifel | Buy | 24 мая 2022 г. | |
| JP Morgan | Overweight | 24 мая 2022 г. | |
| Guggenheim | Buy | 24 мая 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Kohli Aditya | A | 128200 | 128200 | 01 февр 2023 г. |
| Kohli Aditya | A | 821744 | 85466 | 01 февр 2023 г. |
| Borkowski Astrid | A | 77000 | 77000 | 01 февр 2023 г. |
| Borkowski Astrid | A | 219774 | 51333 | 01 февр 2023 г. |
| Maltbie Shane | A | 65000 | 65000 | 01 февр 2023 г. |
| Maltbie Shane | A | 44232 | 43333 | 01 февр 2023 г. |
| HERSHBERG ROBERT | A | 381950 | 381950 | 01 февр 2023 г. |
| HERSHBERG ROBERT | A | 965428 | 187966 | 01 февр 2023 г. |
| TAKEDA PHARMACEUTICAL CO LTD | D | 0 | 5883500 | 30 ноя 2022 г. |
| TAKEDA PHARMACEUTICAL CO LTD | A | 6724000 | 5883500 | 30 ноя 2022 г. |
Новостная лента
HilleVax to Present at the 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
04 янв 2023 г. в 16:05
BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 9, 2023, at 4:30 p.m. EST / 1:30 p.m. PST. HIL-214, HilleVax's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion.
After Plunging 32.4% in 4 Weeks, Here's Why the Trend Might Reverse for HilleVax, Inc. (HLVX)
Zacks Investment Research
14 дек 2022 г. в 11:17
HilleVax, Inc. (HLVX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down 25.2% in 4 Weeks, Here's Why You Should You Buy the Dip in HilleVax, Inc. (HLVX)
Zacks Investment Research
13 дек 2022 г. в 11:17
HilleVax, Inc. (HLVX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Here's Why "Trend" Investors Would Love Betting on HilleVax, Inc. (HLVX)
Zacks Investment Research
18 ноя 2022 г. в 09:55
HilleVax, Inc. (HLVX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
HilleVax to Participate in November Investor Conferences
GlobeNewsWire
10 ноя 2022 г. в 18:30
BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will participate in the Guggenheim Securities 4th Annual Immunology and Neurology Day and the Stifel Healthcare Conference. HIL-214, HilleVax's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b clinical trial NEST-IN1 will be topics of discussion at both events.